Stock Market Reviews

PACB (Pacific Biosciences of California, Inc.) News

Get the latest news, insights, and market updates on PACB (Pacific Biosciences of California, Inc.). Explore the news page 3 on MyTopStock.com for investor discussions, analysis, and real-time stock performance coverage.

• PacBio to Report Fourth Quarter and Full Year 2025 Financial Results on February 12, 2026
  MENLO PARK, Calif., Jan. 27, 2026 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB) announced today that it will hold its quarterly conference call to discuss its fourth quarter and full year 2025 financial results on Thursday, February 12, 2026, at 5:00 pm Eastern Time. The call will be webcast and may be accessed at PacBio’s website at https://investor.pacificbiosciences.com/. Date: Thursday, February 12, 2026, at 5:00 pm ET (2:00 pm PT) Listen live via internet or replay: https://investor.pacificbios
  Jan 27, 2026 - $PACB
• How The New Price Target Is Reframing The Story For Pacific Biosciences (PACB)
  Why the Price Target for Pacific Biosciences of California Matters Now Pacific Biosciences of California is back in focus as investors react to a reset in the stock’s price target, reflecting a fresh read on risks and potential rewards. With no prior reference point provided, this new target stands on its own as a statement about how analysts currently frame the story around the company. Stay tuned to see how you can keep on top of future shifts in this narrative as new information comes...
  Jan 25, 2026 - $PACB
• Pacific Biosciences of California (PACB) Stock Dips While Market Gains: Key Facts
  Pacific Biosciences of California (PACB) closed the most recent trading day at $2.58, moving 3.37% from the previous trading session.
  Jan 23, 2026 - $PACB
• Pacific Biosciences of California (PACB) Dips More Than Broader Market: What You Should Know
  Pacific Biosciences of California (PACB) closed at $2.21 in the latest trading session, marking a -5.96% move from the prior day.
  Jan 16, 2026 - $PACB
• 3 Unpopular Stocks That Concern Us
  Wall Street’s bearish price targets for the stocks in this article signal serious concerns. Such forecasts are uncommon in an industry where maintaining cordial corporate relationships often trumps delivering the hard truth.
  Jan 16, 2026 - $PACB
• PacBio Stock Up on HiFi Sequencing Adoption for Major SUDC Research
  PACB stock jumps as HiFi whole-genome sequencing becomes first-line in major SUDC research, highlighting adoption momentum.
  Jan 15, 2026 - $PACB
• PacBio HiFi Adopted as First-Line Sequencing Approach to Investigate Sudden Unexplained Death in Childhood (SUDC)
  Trios from 200 families who have lost a child to SUDC to be sequenced on PacBio’s Revio system with SPRQ-Nx chemistry, enabling increased diagnostic yield for grieving familiesMENLO PARK, Calif., Jan. 12, 2026 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB), developer of the world's most advanced sequencing technologies, today announced that a UW Medicine and Seattle Children’s research effort led by Danny Miller, MD, PhD, and Alexandra Keefe, MD, PhD, will employ PacBio HiFi whole-genome sequencing a
  Jan 12, 2026 - $PACB
• PacBio Announces Preliminary Fourth Quarter and Full Year 2025 Revenue
  Q4 2025 revenue growth of 14% year-over-year, driven by strong Revio and Vega shipments and record consumables revenueMENLO PARK, Calif., Jan. 12, 2026 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB), a leading developer of high-quality, highly accurate sequencing solutions, announced preliminary unaudited revenue for the fourth quarter of 2025 and full year 2025 of $44.6 million and $160.0 million representing year-over-year growth of 14% and 4%, respectively. “We finished the year with strong moment
  Jan 12, 2026 - $PACB
• PacBio Announces Plans for Collaboration With n-Lorem Foundation and EspeRare to Advance Precision Therapies for Rare Genetic Diseases
  The planned collaboration highlights the role of complete genome resolution in scaling n-of-1 therapeutic modelsMENLO PARK, Calif., Jan. 12, 2026 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB), developer of the world's most advanced sequencing technologies, today announced plans to pursue a strategic collaboration with the n-Lorem Foundation and EspeRare that we believe will position long-read whole-genome sequencing as enabling infrastructure to support the development of individualized antisense ol
  Jan 12, 2026 - $PACB
• How PacBio (PACB) Is Seeing Its Fair Value Story Shift After ARK’s Share Purchase
  What Is Actually Changing In PacBio’s Fair Value Story? Analysts have lifted their fair value estimate for Pacific Biosciences of California from US$2.36 to US$2.50, a move that sits on a small set of updated assumptions rather than any sweeping change in the story. The discount rate used in their models has shifted from 10.58% to 10.31%, and the long term revenue growth assumption has been adjusted from 13.42% to 13.77%, reflecting slightly higher confidence in PacBio’s ability to grow if it...
  Jan 11, 2026 - $PACB